Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 55, Issue 5

Issues

Identification of a novel microRNA, miR-4449, as a potential blood based marker in multiple myeloma

Xianjuan Shen
  • Surgical Comprehensive Laboratory, Affiliated Hospital of Nantong University, Nantong, P.R. China
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Yan Ye / Jing Qi
  • Surgical Comprehensive Laboratory, Affiliated Hospital of Nantong University, Nantong, P.R. China
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Wei Shi
  • Surgical Comprehensive Laboratory, Affiliated Hospital of Nantong University, Nantong, P.R. China
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Xinhua Wu
  • Surgical Comprehensive Laboratory, Affiliated Hospital of Nantong University, Nantong, P.R. China
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Hongbing Ni / Hui Cong / Shaoqing Ju
  • Corresponding author
  • Laboratory Medicine Center, Affiliated Hospital of Nantong University, #20 Xisi Road, Nantong 226001, JS, P.R. China
  • Surgical Comprehensive Laboratory, Affiliated Hospital of Nantong University, Nantong, P.R. China, Phone/Fax: +86 0513 85052610
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2016-05-06 | DOI: https://doi.org/10.1515/cclm-2015-1108

Abstract

Background:

miRNAs act in diverse biological processes including development, cell growth, apoptosis, and hematopoiesis, suggesting their role in cancer.

Methods:

We examined the miRNAs perturbed in CD138+ primary multiple myeloma (MM) cells, using microarray analysis and real-time quantitative PCR (RT-qPCR). Serum miR-4449 expression levels were detected from 71 primary MM patients and 46 healthy controls by RT-qPCR.

Results:

Our analysis revealed up-regulation of 54 and down-regulation of 28 miRNAs in MM subjects compared to healthy controls. miR-4449 has not been reported in MM. It was found that the relative expression of bone marrow miR-4449 in MM patients (2.14±1.42) was higher than that in healthy controls (0.815±0.165) (U=8, p=0.0093). The relative expression of serum miR-4449 in MM patients (2.11±2.10) was significantly higher than that in healthy controls (0.357±0.235) (U=374, p<0.0001) and was significantly correlated with β2M, λ light and κ light chain concentration (r=0.480, p=0.0003; r=0.560, p<0.0001; r=0.560, p<0.0001), but not correlated with the lactate dehydrogenase (LDH) concentration (r=0.247, p=0.0611). The area under the curve (AUC) of the receiver-operating characteristics (ROC) curve of serum miR-4449 was 0.885 (95% CI, 0.826–0.945), which is higher than for other markers. Combining miR-4449, λ light chain, and β2M together, the sensitivity was highest compared with λ light chain or β2M alone, or combined.

Conclusions:

The expression levels of serum miR-4449 in MM patients were significantly higher than in healthy controls, suggesting that it may prove to be useful in the auxiliary diagnosis of MM.

Keywords: auxiliary diagnosis; miR-4449; multiple myeloma; real-time quantitative PCR

References

  • 1.

    Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7:585–98.Google Scholar

  • 2.

    Unno K, Zhou Y, Zimmerman T, Platanias LC, Wickrema A. Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma. Leuk Lymphoma 2009;50:1865–71.Google Scholar

  • 3.

    Dalmay T. MicroRNAs and cancer. J Intern Med 2008;263:366–75.Google Scholar

  • 4.

    Lee YS, Dutta A. MicroRNAs in Cancer. Annu Rev Pathol 2009;4:199–227.Google Scholar

  • 5.

    Bi C, Chng WJ. MicroRNA: important player in the pathobiology of multiple myeloma. Biomed Res Int 2014;2014:521586.Google Scholar

  • 6.

    He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828–33.Google Scholar

  • 7.

    Löffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermüller J, Kretzschmar AK, et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007;110:1330–3.Google Scholar

  • 8.

    Peng J, Thakur A, Zhang S, Dong Y, Wang X, Yuan R, et al. Expressions of miR-181a and miR-20a in RPMI8226 cell line and their potential as biomarkers for multiple myeloma. Tumour Biol 2015;36: 8545–52.Google Scholar

  • 9.

    Chen L, Li C, Zhang R, Gao X, Qu X, Zhao M, et al. miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. Cancer Lett 2011;309:62–70.Google Scholar

  • 10.

    Rio-Machin A, Ferreira BI, Henry T, Gómez-López G, Agirre X, Alvarez S, et al. Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype leukemia 2013;27:925–31.Google Scholar

  • 11.

    Wu P, Agnelli L, Walker BA, Todoerti K, Lionetti M, Johnson DC, et al. Improved risk stratification in myeloma using a microRNA-based classifier. Br J Haematol 2013;162:348–59.Google Scholar

  • 12.

    Seckinger A, Meißner T, Moreaux J, Benes V, Hillengass J, Castoldi M, et al. miRNAs in multiple myeloma – a survival relevant complex regulator of gene expression. Oncotarget 2015;6:39165–83.Google Scholar

  • 13.

    Chi J, Ballabio E, Chen XH, Kušec R, Taylor S, Hay D, et al. MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct 2011;6:23.Google Scholar

  • 14.

    Huang JJ, Yu J, Li JY, Liu YT, Zhong RQ. Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma. Med Oncol 2012;29:2402–8.Google Scholar

  • 15.

    Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012;87:78–88.Google Scholar

  • 16.

    Agnelli L, Fabris S, Bicciato S, Basso D, Baldini L, Morabito F, et al. Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. Br J Haematol 2007;136:565–73.Google Scholar

  • 17.

    Fonseca R, Monge J, Dimopoulos MA. Staging and prognostication of multiple myeloma. Expert Rev Hematol 2014;7:21–31.Google Scholar

  • 18.

    Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 2012;18:6260–70.Google Scholar

  • 19.

    Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008;105:12885–90.Google Scholar

  • 20.

    Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, et al. M icroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009;113:6669–80.Google Scholar

  • 21.

    Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams DR, et al. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci USA 2010;107:7904–9.Google Scholar

  • 22.

    Tagliaferri P, Rossi M, Di Martino MT, Amodio N, Leone E, Gulla A, et al. Promises and challenges of MicroRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets 2012;12:838–46.Google Scholar

  • 23.

    Sevcikova S, Kubiczkova L, Sedlarikova L, Slaby O, Hajek R. Serum miR-29a as a marker of multiple myeloma. Leuk Lymphoma 2013;54:189–91.Google Scholar

  • 24.

    Kubiczkova L, Kryukov F, Slaby O, Dementyeva E, Jarkovsky J, Nekvindova J, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica 2014;99:511–8.Google Scholar

  • 25.

    Duttagupta R, Jiang R, Gollub J, Getts RC, Jones KW. Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One 2011;6:e20769.CrossrefGoogle Scholar

  • 26.

    Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg CR, et al. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One 2012;7:e29770.Google Scholar

  • 27.

    Yu J, Qiu X, Shen X, Shi W, Wu X, Gu G, et al. miR-202 expression concentration and its clinical significance in the serum of multiple myeloma patients. Ann Clin Biochem 2014;51(Pt 5):543–9.Google Scholar

About the article

aXianjuan Shen and Yan Ye contributed equally as first authors.


Received: 2015-11-11

Accepted: 2016-04-04

Published Online: 2016-05-06

Published in Print: 2017-05-01


Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: Grand support: the National Nature Science Foundation of China (81301498; 81271920; 81201351); Jiangsu Provincial Medical Innovation Team and Leading Talents (LJ201133); the Scientific Research Subject of Jiangsu Provincial Health Department (H201422; H201526); and translational medicine project of Affiliated Hospital of Nantong University (TDF-zh201407, TDF-zh201406).

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 55, Issue 5, Pages 748–754, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2015-1108.

Export Citation

©2017 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Mohammad H. Pourhanifeh, Maryam Mahjoubin‐Tehran, Alimohammad Shafiee, Sarah Hajighadimi, Sanaz Moradizarmehri, Hamed Mirzaei, and Zatollah Asemi
IUBMB Life, 2019
[2]
Ning-Sheng Lai, Hui-Chun Yu, Chien-Hsueh Tung, Kuang-Yung Huang, Hsien-Bin Huang, and Ming-Chi Lu
Arthritis Research & Therapy, 2018, Volume 20, Number 1
[3]
Qian Yang, Xianjuan Shen, Zhangyao Su, and Shaoqing Ju
Journal of Cellular Physiology, 2018
[4]
Xianjuan Shen, Yan Zhang, Xian Wu, Yuehua Guo, Wei Shi, Jing Qi, Hui Cong, Xudong Wang, Xinhua Wu, and Shaoqing Ju
Cancer Biomarkers, 2017, Volume 18, Number 3, Page 257

Comments (0)

Please log in or register to comment.
Log in